Press Releases

March 24, 2020

PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING 

March 18, 2020

ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results

February 26, 2020

ProMIS Neurosciences initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease

Press Archives

In the News

March 4, 2020

Pharma Boardroom – Alzheimer’s Disease Treatment: Canadian-Led Innovation Post-Aducanumab

March 4, 2020

Neurology Live – Aducanumab Reinvigorates the Fight Against Alzheimer Disease

February 20, 2020

Fierce Pharma – Pharma Buffett’s a believer: Berkshire bets $192M on Biogen ahead of key Alzheimer’s filing

News Archives

Presentations

January 27, 2020

Sachs Neuroscience Innovation Forum Presentation

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

September 10, 2019

Executive Chairman Gene William’s Presentation at the HC Wainwright Investor Conference

Presentations Archives

Videos

November 6, 2019

ProMIS Neurosciences: “Best in Class” therapy for misfolded protein diseases, based on a proprietary discovery platform

August 6, 2019

Dr. James Kupiec’s update from AAIC 2019: Demonstrating Early Proof-of-Concept with Biomarkers and Focused Patient Populations

July 18, 2019

ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019 

Video Archives